Excalipoint's $69M Launch Signals New Era for China's Global Biotech Bid

SHANGHAI, China – March 18, 2026 – A new biotechnology firm, Excalipoint Therapeutics, has emerged from stealth with a staggering $68.7 million in seed financing, signaling a major vote of confidence from global investors and marking one of the largest early-stage funding rounds for a Chinese biotech company. The Shanghai-based venture is poised to tackle some of the toughest challenges in medicine with its next-generation T-cell engager (TCE) therapies for cancer and autoimmune diseases.

More than just another well-funded startup, Excalipoint represents a pioneering "China NewCo model" that integrates experienced founders, advanced technology platforms, and significant capital to accelerate drug development on a global scale. In a demonstration of its rapid execution, the company has already advanced its lead candidate into a Phase I/II clinical trial just months after its inception, a pace that is turning heads across the industry.

A New Model for Global Biotech Innovation

At the heart of Excalipoint's strategy is a novel operational framework designed to harness the unique strengths of China's maturing biotech ecosystem. The "China NewCo model" moves beyond traditional startup structures by launching with a combination of seasoned leadership, a foundational technology pipeline, and substantial venture backing from day one. This integrated approach is designed to compress development timelines and de-risk the notoriously long and expensive process of bringing a new drug to market.

The company’s impressive financial backing was secured in two tranches. An initial $41 million seed round in August 2025 was co-led by HSG, Apricot Capital, and Yuanbio Venture Capital. After hitting key milestones, a $27.7 million extension was co-led by MPCi (formerly Matrix Partners China) and Centurium Capital, with significant participation from global heavyweights Lilly Asia Ventures (LAV) and Eisai Innovation Inc., the corporate venture arm of Japan's Eisai.

This model leverages China's sophisticated clinical research infrastructure, a deep network of experienced principal investigators, and access to large, diverse patient populations. "By combining science and capital with China’s clinical development efficiency and access to large patient populations, we can rapidly generate clinical data," stated Dr. Lei Fang, Co-Founder and CEO of Excalipoint, in the company's launch announcement. He emphasized that this progress reflects the strength of a Chinese biotech ecosystem that has "become an essential part of the global innovation value chain."

The strategy allows the company to pursue a diversified pipeline, mitigating the single-asset risk that plagues many smaller biotechs and positioning it for strategic partnerships and out-licensing deals that can drive long-term value.

The Science of Conquering 'Undruggable' Cancers

Excalipoint is focusing its considerable resources on T-cell engagers (TCEs), a powerful class of immunotherapy that acts like a molecular matchmaker, redirecting a patient's own T-cells to find and destroy cancer cells. While TCEs have seen remarkable success in blood cancers, their effectiveness against solid tumors has been hampered by several biological barriers.

Many solid tumors are immunologically "cold," lacking the T-cell infiltration necessary for an effective attack. Furthermore, the tumor microenvironment (TME) often creates an immunosuppressive shield that neutralizes immune cells that do manage to arrive. Finally, many promising tumor-associated antigens have been considered "undruggable" due to their presence on healthy tissues, raising the risk of severe off-target toxicity.

Excalipoint aims to overcome these hurdles with a suite of three proprietary technology platforms:

• TOPAbody Platform: This technology creates tri-specific antibodies designed to not only engage T-cells (via CD3) and target tumor cells but also provide a powerful co-stimulatory signal (via 4-1BB). This additional signal is intended to fully activate T-cells, boost their proliferation and survival, and effectively convert "cold" tumors into "hot" ones that are ripe for an immune assault.

• T-Cell Immune Shield Platform: To counteract the hostile tumor microenvironment, this platform integrates TME-blocking functionalities directly into the TCE molecule. This "shield" is designed to protect the redirected T-cells from the immunosuppressive signals within the tumor, allowing them to function more effectively and durably.

• TCE Probody Platform: Addressing the critical challenge of on-target, off-tumor toxicity, this platform uses a "masking" technology. The TCE is engineered as a "probody" that remains inactive in circulation. It is designed to be selectively activated only within the tumor microenvironment, theoretically unmasking its cancer-killing potential precisely where it is needed and sparing healthy tissues.

Together, these platforms form the scientific bedrock of the company's ambition to create safer, more durable, and more broadly effective immunotherapies for difficult-to-treat diseases.

A Pipeline Built for Speed and Value

The company's strategy is not just theoretical. In a remarkable display of execution, Excalipoint dosed the first patient in a Phase I/II clinical trial for its lead asset, EXP011, in October 2025—a mere two months after its founding. This rapid clinical entry was made possible by the "NewCo" model and the deep experience of its co-founders, CEO Dr. Lei Fang and CFO/CBO Jielun Zhu, who both have track records at major biotech firms like I-Mab Biopharma.

EXP011, derived from the TOPAbody platform, is a tri-specific antibody targeting DLL3, an antigen expressed in aggressive cancers like small cell lung cancer (SCLC) and neuroendocrine tumors. By simultaneously engaging CD3 on T-cells and providing a 4-1BB co-stimulatory signal, the therapy aims to generate a potent and sustained anti-tumor response in these high-unmet-need indications.

Beyond its lead candidate, the company is building a diversified pipeline to tackle a range of diseases. Other programs include EXP012, another tri-specific antibody for colorectal, gastric, and pancreatic cancers; EXP016 and EXP017, which leverage the TOPAbody and Immune Shield platforms for other solid tumors; EP101, which uses the Pro-TCE platform for challenging antigens; and EXP015, which extends the TOPAbody technology into IgG-associated autoimmune diseases.

Investor Confidence in a Global Contender

The high-caliber syndicate of investors underscores the belief that Excalipoint is not just a domestic player but a potential global contender. The participation of both top-tier Chinese venture firms and the corporate venture arms of global pharmaceutical giants provides both financial muscle and strategic validation.

"MPCi is deeply engaged in healthcare, focusing on science-driven innovative enterprises with core technological barriers. Excalipoint is our highly recognized next-generation TCE innovation powerhouse," said David Su, Founding Managing Partner at MPCi. He praised the company's "three independent and cutting-edge technology platforms" and its potential to "break down traditional TCE treatment bottlenecks."

This sentiment was echoed by Centurium Capital. "We believe Excalipoint is among the most promising next-generation TCE companies globally," said Vicky Li, Executive Director at the firm. She highlighted the combination of "strong scientific leadership, a differentiated pipeline, and an impressive track record of execution."

The inclusion of LAV and Eisai Innovation Inc. in the financing round is particularly noteworthy. It signals strong interest from established global biopharma ecosystems and opens potential avenues for future cross-border partnerships and licensing deals. This blend of local execution and global validation is central to Excalipoint's mission to translate its innovative science into therapies that can address unmet medical needs worldwide.